Integrated proteomics and metabolomics analyses reveal new insights into the antitumor effects of valproic acid plus simvastatin combination in a prostate cancer xenograft model associated with downmodulation of YAP/TAZ signaling

Abstract Background Despite advancements in therapeutic approaches, including taxane-based chemotherapy and androgen receptor-targeting agents, metastatic castration-resistant prostate cancer (mCRPC) remains an incurable tumor, highlighting the need for novel strategies that can target the complexit...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Federica Iannelli, Rita Lombardi, Susan Costantini, Maria Serena Roca, Laura Addi, Francesca Bruzzese, Elena Di Gennaro, Alfredo Budillon, Biagio Pucci
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	BMC 2024-11-01
סדרה:	Cancer Cell International
נושאים:	Drug repurposing Valproic acid Simvastatin Proteomics Metabolomics Prostate cancer
גישה מקוונת:	https://doi.org/10.1186/s12935-024-03573-1
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!